<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34372613</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>7</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>20</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>The Molecular Evolution of Type 2 Vaccine-Derived Polioviruses in Individuals with Primary Immunodeficiency Diseases.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1407</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v13071407</ELocationID><Abstract><AbstractText>The oral poliovirus vaccine (OPV), which prevents person-to-person transmission of poliovirus by inducing robust intestinal immunity, has been a crucial tool for global polio eradication. However, polio outbreaks, mainly caused by type 2 circulating vaccine-derived poliovirus (cVDPV2), are increasing worldwide. Meanwhile, immunodeficiency-associated vaccine-derived poliovirus (iVDPV) is considered another risk factor during the final stage of global polio eradication. Patients with primary immunodeficiency diseases are associated with higher risks for long-term iVDPV infections. Although a limited number of chronic iVDPV excretors were reported, the recent identification of a chronic type 2 iVDPV (iVDPV2) excretor in the Philippines highlights the potential risk of inapparent iVDPV infection for expanding cVDPV outbreaks. Further research on the genetic characterizations and molecular evolution of iVDPV2, based on comprehensive iVDPV surveillance, will be critical for elucidating the remaining risk of iVDPV2 during the post-OPV era.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kitamura</LastName><ForeName>Kouichi</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-9692-8724</Identifier><AffiliationInfo><Affiliation>Department of Virology II, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama-shi, Tokyo 208-0011, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimizu</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-2987-2377</Identifier><AffiliationInfo><Affiliation>Department of Virology II, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama-shi, Tokyo 208-0011, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D060740" MajorTopicYN="N">Disease Eradication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019143" MajorTopicYN="Y">Evolution, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016867" MajorTopicYN="Y">Immunocompromised Host</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000081207" MajorTopicYN="N">Primary Immunodeficiency Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">global polio eradication</Keyword><Keyword MajorTopicYN="N">immunodeficiency-associated vaccine-derived poliovirus</Keyword><Keyword MajorTopicYN="N">oral poliovirus vaccine</Keyword><Keyword MajorTopicYN="N">poliovirus</Keyword><Keyword MajorTopicYN="N">vaccine-derived poliovirus</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>10</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34372613</ArticleId><ArticleId IdType="pmc">PMC8310373</ArticleId><ArticleId IdType="doi">10.3390/v13071407</ArticleId><ArticleId IdType="pii">v13071407</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adams A., Salisbury D.M. Eradicating polio. Science. 2015;350:609. doi: 10.1126/science.aad7294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad7294</ArticleId><ArticleId IdType="pubmed">26542542</ArticleId></ArticleIdList></Reference><Reference><Citation>Makoni M. Africa eradicates wild polio. Lancet Microbe. 2020;1:e243. doi: 10.1016/S2666-5247(20)30152-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(20)30152-X</ArticleId><ArticleId IdType="pmc">PMC7541043</ArticleId><ArticleId IdType="pubmed">33047110</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuma J.N., Wilkinson A.L., Diop O.M., Jorba J., Gardner T., Snider C.J., Anand A., Ahmed J. Surveillance to track progress toward polio eradication&#x2014;Worldwide, 2019&#x2013;2020. MMWR Morb. Mortal. Wkly. Rep. 2021;70:667&#x2013;673. doi: 10.15585/mmwr.mm7018a2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7018a2</ArticleId><ArticleId IdType="pmc">PMC9368747</ArticleId><ArticleId IdType="pubmed">33956779</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative  Wild Poliovirus List.  [(accessed on 2 July 2021)]; Available online:  https://polioeradication.org/wp-content/uploads/2021/06/weekly-polio-analyses-WPV-20210615.pdf.</Citation></Reference><Reference><Citation>Cochi S.L., Pallansch M.A. The long and winding road to eradicate vaccine-related polioviruses. J. Infect. Dis. 2021;223:7&#x2013;9. doi: 10.1093/infdis/jiaa393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa393</ArticleId><ArticleId IdType="pmc">PMC10546420</ArticleId><ArticleId IdType="pubmed">32621744</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov K., Ehrenfeld E., Agol V.I., Wimmer E. Polio eradication at the crossroads. Lancet Glob. Health. 2021 doi: 10.1016/S2214-109X(21)00205-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(21)00205-9</ArticleId><ArticleId IdType="pubmed">34118192</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative  Circulating Vaccine-Derived Poliovirus.  [(accessed on 2 July 2021)]; Available online:  http://polioeradication.org/polio-today/polio-now/this-week/circulating-vaccine-derived-poliovirus/</Citation></Reference><Reference><Citation>Alleman M.M., Jorba J., Greene S.A., Diop O.M., Iber J., Tallis G., Goel A., Wiesen E., Wassilak S.G.F., Burns C.C. Update on vaccine-derived poliovirus outbreaks&#x2014;Worldwide, July 2019&#x2013;February 2020. MMWR Morb. Mortal. Wkly. Rep. 2020;69:489&#x2013;495. doi: 10.15585/mmwr.mm6916a1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6916a1</ArticleId><ArticleId IdType="pmc">PMC7188410</ArticleId><ArticleId IdType="pubmed">32324719</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns C.C., Diop O.M., Sutter R.W., Kew O.M. Vaccine-derived polioviruses. J. Infect. Dis. 2014;210(Suppl. S1):S283&#x2013;S293. doi: 10.1093/infdis/jiu295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu295</ArticleId><ArticleId IdType="pubmed">25316847</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan D., Wang D., Zhang Y., Li X., Tang H., Guan J., Song Y., Zhu S., Xu W. Implication of a High Risk for Type 2 Vaccine-Derived Poliovirus Emergence and Transmission After the Switch From Trivalent to Bivalent Oral Poliovirus Vaccine. J. Infect. Dis. 2021;223:113&#x2013;118. doi: 10.1093/infdis/jiaa386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa386</ArticleId><ArticleId IdType="pubmed">32621746</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer E., Sikka N., Durry E., Datta D. Notes from the field: CDC polio surge response to expanding outbreaks of Type 2 circulating vaccine-derived poliovirus&#x2014;Africa and Philippines, September 2019&#x2013;March 2020. MMWR Morb. Mortal. Wkly. Rep. 2020;69:1182&#x2013;1183. doi: 10.15585/mmwr.mm6934a6.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6934a6</ArticleId><ArticleId IdType="pmc">PMC7451978</ArticleId><ArticleId IdType="pubmed">32853189</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin G., Diop O.M., Humayun A., Shahmahmoodi S., El-Sayed Z.A., Triki H., Rey G., Avagyan T., Grabovac V., Jorba J., et al. Update on immunodeficiency-associated vaccine-derived polioviruses&#x2014;Worldwide, July 2018&#x2013;December 2019. MMWR Morb. Mortal. Wkly. Rep. 2020;69:913&#x2013;917. doi: 10.15585/mmwr.mm6928a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6928a4</ArticleId><ArticleId IdType="pmc">PMC7366852</ArticleId><ArticleId IdType="pubmed">32673297</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghamohammadi A., Abolhassani H., Kutukculer N., Wassilak S.G., Pallansch M.A., Kluglein S., Quinn J., Sutter R.W., Wang X., Sanal O., et al. Patients with primary immunodeficiencies are a reservoir of poliovirus and a risk to polio eradication. Front. Immunol. 2017;8:685. doi: 10.3389/fimmu.2017.00685.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00685</ArticleId><ArticleId IdType="pmc">PMC5468416</ArticleId><ArticleId IdType="pubmed">28952612</ArticleId></ArticleIdList></Reference><Reference><Citation>Mbala-Kingebeni P., Pratt C., Mutafali-Ruffin M., Pauthner M.G., Bile F., Nkuba-Ndaye A., Black A., Kinganda-Lusamaki E., Faye M., Aziza A., et al. Ebola virus transmission initiated by relapse of systemic Ebola virus disease. N. Engl. J. Med. 2021;384:1240&#x2013;1247. doi: 10.1056/NEJMoa2024670.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2024670</ArticleId><ArticleId IdType="pmc">PMC7888312</ArticleId><ArticleId IdType="pubmed">33789012</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp S.A., Collier D.A., Datir R.P., Ferreira I., Gayed S., Jahun A., Hosmillo M., Rees-Spear C., Mlcochova P., Lumb I.U., et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021;592:277&#x2013;282. doi: 10.1038/s41586-021-03291-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03291-y</ArticleId><ArticleId IdType="pmc">PMC7610568</ArticleId><ArticleId IdType="pubmed">33545711</ArticleId></ArticleIdList></Reference><Reference><Citation>Perelygina L., Chen M.H., Suppiah S., Adebayo A., Abernathy E., Dorsey M., Bercovitch L., Paris K., White K.P., Krol A., et al. Infectious vaccine-derived rubella viruses emerge, persist, and evolve in cutaneous granulomas of children with primary immunodeficiencies. PLoS Pathog. 2019;15:e1008080. doi: 10.1371/journal.ppat.1008080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1008080</ArticleId><ArticleId IdType="pmc">PMC6837625</ArticleId><ArticleId IdType="pubmed">31658304</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue K.S., Stevens-Ayers T., Campbell A.P., Englund J.A., Pergam S.A., Boeckh M., Bloom J.D. Parallel evolution of influenza across multiple spatiotemporal scales. Elife. 2017:6. doi: 10.7554/eLife.26875.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.26875</ArticleId><ArticleId IdType="pmc">PMC5487208</ArticleId><ArticleId IdType="pubmed">28653624</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns C.C., Shaw J., Jorba J., Bukbuk D., Adu F., Gumede N., Pate M.A., Abanida E.A., Gasasira A., Iber J., et al. Multiple independent emergences of Type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria. J. Virol. 2013;87:4907&#x2013;4922. doi: 10.1128/JVI.02954-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02954-12</ArticleId><ArticleId IdType="pmc">PMC3624331</ArticleId><ArticleId IdType="pubmed">23408630</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu. Rev. Microbiol. 2005;59:587&#x2013;635. doi: 10.1146/annurev.micro.58.030603.123625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.micro.58.030603.123625</ArticleId><ArticleId IdType="pubmed">16153180</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew O.M., Wright P.F., Agol V.I., Delpeyroux F., Shimizu H., Nathanson N., Pallansch M.A. Circulating vaccine-derived polioviruses: Current state of knowledge. Bull. World Health Organ. 2004;82:16&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2585883</ArticleId><ArticleId IdType="pubmed">15106296</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative  Polio Eradication and Endgame Strategic Plan 2013&#x2013;2018.  [(accessed on 2 July 2021)]; Available online:  https://polioeradication.org/wp-content/uploads/2016/07/PEESP_EN_A4.pdf.</Citation></Reference><Reference><Citation>Garon J., Seib K., Orenstein W.A., Ramirez Gonzalez A., Chang Blanc D., Zaffran M., Patel M. Polio endgame: The global switch from tOPV to bOPV. Expert Rev. Vaccines. 2016;15:693&#x2013;708. doi: 10.1586/14760584.2016.1140041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2016.1140041</ArticleId><ArticleId IdType="pubmed">26751187</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative Introduction of inactivated poliovirus vaccine and switch from trivalent to bivalent oral poliovirus vaccine&#x2014;Worldwide, 2013&#x2013;2016. MMWR Morb. Mortal. Wkly. Rep. 2015;64:699&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4584682</ArticleId><ArticleId IdType="pubmed">26135591</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative  Global Circulating Vaccine-Derived Poliovirus (cVDPV) as of 01 June 2021.  [(accessed on 2 July 2021)]; Available online:  https://polioeradication.org/wp-content/uploads/2021/06/weekly-polio-analyses-cVDPV-20210601.pdf.</Citation></Reference><Reference><Citation>Macklin G.R., O&#x2019;Reilly K.M., Grassly N.C., Edmunds W.J., Mach O., Santhana Gopala Krishnan R., Voorman A., Vertefeuille J.F., Abdelwahab J., Gumede N., et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. Science. 2020;368:401&#x2013;405. doi: 10.1126/science.aba1238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aba1238</ArticleId><ArticleId IdType="pmc">PMC10805349</ArticleId><ArticleId IdType="pubmed">32193361</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;ez-Llorens X., Bandyopadhyay A.S., Gast C., Leon T., DeAntonio R., Jimeno J., Caballero M.I., Aguirre G., Oberste M.S., Weldon W.C., et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: Two clinical trials. Lancet. 2021;397:27&#x2013;38. doi: 10.1016/S0140-6736(20)32540-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32540-X</ArticleId><ArticleId IdType="pmc">PMC7811205</ArticleId><ArticleId IdType="pubmed">33308427</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh M.T., Bujaki E., Dolan P.T., Smith M., Wahid R., Konz J., Weiner A.J., Bandyopadhyay A.S., Van Damme P., De Coster I., et al. Engineering the live-attenuated polio vaccine to prevent reversion to virulence. Cell Host Microbe. 2020;27:736&#x2013;751.e8. doi: 10.1016/j.chom.2020.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.04.003</ArticleId><ArticleId IdType="pmc">PMC7566161</ArticleId><ArticleId IdType="pubmed">32330425</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P., De Coster I., Bandyopadhyay A.S., Revets H., Withanage K., De Smedt P., Suykens L., Oberste M.S., Weldon W.C., Costa-Clemens S.A., et al. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: A double-blind, single-centre phase 1 study. Lancet. 2019;394:148&#x2013;158. doi: 10.1016/S0140-6736(19)31279-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)31279-6</ArticleId><ArticleId IdType="pmc">PMC6626986</ArticleId><ArticleId IdType="pubmed">31174831</ArticleId></ArticleIdList></Reference><Reference><Citation>Zomahoun D.J., Burman A.L., Snider C.J., Chauvin C., Gardner T., Lickness J.S., Ahmed J.A., Diop O., Gerber S., Anand A. Impact of COVID-19 pandemic on global poliovirus surveillance. MMWR Morb. Mortal. Wkly. Rep. 2021;69:1648&#x2013;1652. doi: 10.15585/mmwr.mm695152a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm695152a4</ArticleId><ArticleId IdType="pmc">PMC9191906</ArticleId><ArticleId IdType="pubmed">33382673</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Statement Following the Twenty-Eighth IHR Emergency Committee for Polio.  [(accessed on 2 July 2021)]; Available online:  https://www.who.int/news/item/21-05-2021-statement-following-the-twenty-eighth-ihr-emergency-committee-for-polio.</Citation></Reference><Reference><Citation>Jorba J., Diop O.M., Iber J., Henderson E., Zhao K., Sutter R.W., Wassilak S.G.F., Burns C.C. Update on vaccine-derived polioviruses&#x2014;Worldwide, January 2017&#x2013;June 2018. MMWR Morb. Mortal. Wkly. Rep. 2018;67:1189&#x2013;1194. doi: 10.15585/mmwr.mm6742a5.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6742a5</ArticleId><ArticleId IdType="pmc">PMC6290814</ArticleId><ArticleId IdType="pubmed">30359342</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaghaghi M., Soleyman-Jahi S., Abolhassani H., Yazdani R., Azizi G., Rezaei N., Barbouche M.R., McKinlay M.A., Aghamohammadi A. New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection; systematic review of over 5 decades of data. Vaccine. 2018;36:1711&#x2013;1719. doi: 10.1016/j.vaccine.2018.02.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.02.059</ArticleId><ArticleId IdType="pubmed">29478755</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention Update on vaccine-derived polioviruses. MMWR Morb. Mortal. Wkly. Rep. 2006;55:1093&#x2013;1097.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035927</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorgensen D., Pons-Salort M., Shaw A.G., Grassly N.C. The role of genetic sequencing and analysis in the polio eradication programme. Virus Evol. 2020;6:veaa040. doi: 10.1093/ve/veaa040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ve/veaa040</ArticleId><ArticleId IdType="pmc">PMC7409915</ArticleId><ArticleId IdType="pubmed">32782825</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern A., Yeh M.T., Zinger T., Smith M., Wright C., Ling G., Nielsen R., Macadam A., Andino R. The evolutionary pathway to virulence of an RNA virus. Cell. 2017;169:35&#x2013;46.e19. doi: 10.1016/j.cell.2017.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.03.013</ArticleId><ArticleId IdType="pmc">PMC5787669</ArticleId><ArticleId IdType="pubmed">28340348</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald S.L., Weldon W.C., Wei L., Chen Q., Shaw J., Zhao K., Jorba J., Kew O.M., Pallansch M.A., Burns C.C., et al. Neutralization capacity of highly divergent type 2 vaccine-derived polioviruses from immunodeficient patients. Vaccine. 2020;38:3042&#x2013;3049. doi: 10.1016/j.vaccine.2020.02.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.02.035</ArticleId><ArticleId IdType="pmc">PMC11382130</ArticleId><ArticleId IdType="pubmed">32089462</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao K., Jorba J., Shaw J., Iber J., Chen Q., Bullard K., Kew O.M., Burns C.C. Are circulating type 2 vaccine-derived polioviruses (VDPVs) genetically distinguishable from immunodeficiency-associated VDPVs? Comput. Struct. Biotechnol. J. 2017;15:456&#x2013;462. doi: 10.1016/j.csbj.2017.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2017.09.004</ArticleId><ArticleId IdType="pmc">PMC5671402</ArticleId><ArticleId IdType="pubmed">29276577</ArticleId></ArticleIdList></Reference><Reference><Citation>Schubert A., B&#xf6;ttcher S., Eis-H&#xfc;binger A.M. Two cases of vaccine-derived poliovirus infection in an Oncology Ward. N. Engl. J. Med. 2016;374:1296&#x2013;1298. doi: 10.1056/NEJMc1508104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc1508104</ArticleId><ArticleId IdType="pubmed">27028932</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVries A.S., Harper J., Murray A., Lexau C., Bahta L., Christensen J., Cebelinski E., Fuller S., Kline S., Wallace G.S., et al. Vaccine-derived poliomyelitis 12 years after infection in Minnesota. N. Engl. J. Med. 2011;364:2316&#x2013;2323. doi: 10.1056/NEJMoa1008677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1008677</ArticleId><ArticleId IdType="pubmed">21675890</ArticleId></ArticleIdList></Reference><Reference><Citation>Yakovenko M.L., Korotkova E.A., Ivanova O.E., Eremeeva T.P., Samoilovich E., Uhova I., Gavrilin G.V., Agol V.I. Evolution of the Sabin vaccine into pathogenic derivatives without appreciable changes in antigenic properties: Need for improvement of current poliovirus surveillance. J. Virol. 2009;83:3402&#x2013;3406. doi: 10.1128/JVI.02122-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02122-08</ArticleId><ArticleId IdType="pmc">PMC2655595</ArticleId><ArticleId IdType="pubmed">19129444</ArticleId></ArticleIdList></Reference><Reference><Citation>Adu F., Iber J., Bukbuk D., Gumede N., Yang S.J., Jorba J., Campagnoli R., Sule W.F., Yang C.F., Burns C., et al. Isolation of recombinant type 2 vaccine-derived poliovirus (VDPV) from a Nigerian child. Virus Res. 2007;127:17&#x2013;25. doi: 10.1016/j.virusres.2007.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2007.03.009</ArticleId><ArticleId IdType="pubmed">17449127</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttinelli G., Donati V., Fiore S., Marturano J., Plebani A., Balestri P., Soresina A.R., Vivarelli R., Delpeyroux F., Martin J., et al. Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis. J. Gen. Virol. 2003;84:1215&#x2013;1221. doi: 10.1099/vir.0.18974-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.18974-0</ArticleId><ArticleId IdType="pubmed">12692287</ArticleId></ArticleIdList></Reference><Reference><Citation>Hovi T., Paananen A., Blomqvist S., Savolainen-Kopra C., Al-Hello H., Smura T., Shimizu H., Nadova K., Sobotova Z., Gavrilin E., et al. Characteristics of an environmentally monitored prolonged Type 2 vaccine derived poliovirus shedding episode that stopped without intervention. PLoS ONE. 2013;8:e66849. doi: 10.1371/journal.pone.0066849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0066849</ArticleId><ArticleId IdType="pmc">PMC3729856</ArticleId><ArticleId IdType="pubmed">23935826</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman L.M., Manor Y., Handsher R., Delpeyroux F., McDonough M.J., Halmut T., Silberstein I., Alfandari J., Quay J., Fisher T., et al. Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel. J. Clin. Microbiol. 2000;38:3729&#x2013;3734. doi: 10.1128/JCM.38.10.3729-3734.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.38.10.3729-3734.2000</ArticleId><ArticleId IdType="pmc">PMC87465</ArticleId><ArticleId IdType="pubmed">11015392</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn G., Klapsa D., Wilton T., Stone L., Minor P.D., Martin J. Twenty-eight years of poliovirus replication in an immunodeficient individual: Impact on the global polio eradication initiative. PLoS Pathog. 2015;11:e1005114. doi: 10.1371/journal.ppat.1005114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005114</ArticleId><ArticleId IdType="pmc">PMC4552295</ArticleId><ArticleId IdType="pubmed">26313548</ArticleId></ArticleIdList></Reference><Reference><Citation>Weil M., Rahav G., Somech R., Stauber T., Alfandari J., Weiss L., Silberstein I., Indenbaum V., Or I.B., Mendelson E., et al. First report of a persistent oropharyngeal infection of type 2 vaccine-derived poliovirus (iVDPV2) in a primary immune deficient (PID) patient after eradication of wild type 2 poliovirus. Int. J. Infect. Dis. 2019;83:40&#x2013;43. doi: 10.1016/j.ijid.2019.03.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2019.03.037</ArticleId><ArticleId IdType="pubmed">30953828</ArticleId></ArticleIdList></Reference><Reference><Citation>Weil M., Shulman L.M., Heiman S., Stauber T., Alfandari J., Weiss L., Silberstein I., Indenbaum V., Mendelson E., Sofer D. Prolonged excretion of type-2 poliovirus from a primary immune deficient patient during the transition to a type-2 poliovirus-free world, Israel, 2016. Euro Surveill. 2016:21. doi: 10.2807/1560-7917.ES.2016.21.47.30408.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2016.21.47.30408</ArticleId><ArticleId IdType="pmc">PMC5291147</ArticleId><ArticleId IdType="pubmed">27918258</ArticleId></ArticleIdList></Reference><Reference><Citation>Price M.N., Dehal P.S., Arkin A.P. FastTree 2&#x2013;Approximately maximum-likelihood trees for large alignments. PLoS ONE. 2010;5:e9490. doi: 10.1371/journal.pone.0009490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0009490</ArticleId><ArticleId IdType="pmc">PMC2835736</ArticleId><ArticleId IdType="pubmed">20224823</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorba J., Campagnoli R., De L., Kew O. Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range. J. Virol. 2008;82:4429&#x2013;4440. doi: 10.1128/JVI.02354-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02354-07</ArticleId><ArticleId IdType="pmc">PMC2293050</ArticleId><ArticleId IdType="pubmed">18287242</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaghaghi M., Irannejad M., Abolhassani H., Shahmahmoodi S., Hamidieh A.A., Soleyman-Jahi S., Yazdani R., Azizi G., Aghamohammadi A. Clearing vaccine-derived poliovirus infection following hematopoietic stem cell transplantation: A case report and review of literature. J. Clin. Immunol. 2018;38:610&#x2013;616. doi: 10.1007/s10875-018-0521-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-018-0521-z</ArticleId><ArticleId IdType="pubmed">29948575</ArticleId></ArticleIdList></Reference><Reference><Citation>Odoom J.K., Yunus Z., Dunn G., Minor P.D., Martin J. Changes in population dynamics during long-term evolution of Sabin type 1 poliovirus in an immunodeficient patient. J. Virol. 2008;82:9179&#x2013;9190. doi: 10.1128/JVI.00468-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00468-08</ArticleId><ArticleId IdType="pmc">PMC2546908</ArticleId><ArticleId IdType="pubmed">18596089</ArticleId></ArticleIdList></Reference><Reference><Citation>Valesano A.L., Taniuchi M., Fitzsimmons W.J., Islam M.O., Ahmed T., Zaman K., Haque R., Wong W., Famulare M., Lauring A.S. The early evolution of oral poliovirus vaccine is shaped by strong positive selection and tight transmission bottlenecks. Cell Host Microbe. 2021;29:32&#x2013;43.e4. doi: 10.1016/j.chom.2020.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.10.011</ArticleId><ArticleId IdType="pmc">PMC7815045</ArticleId><ArticleId IdType="pubmed">33212020</ArticleId></ArticleIdList></Reference><Reference><Citation>Famulare M., Chang S., Iber J., Zhao K., Adeniji J.A., Bukbuk D., Baba M., Behrend M., Burns C.C., Oberste M.S. Sabin vaccine reversion in the field: A comprehensive analysis of Sabin-like poliovirus isolates in Nigeria. J. Virol. 2016;90:317&#x2013;331. doi: 10.1128/JVI.01532-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01532-15</ArticleId><ArticleId IdType="pmc">PMC4702576</ArticleId><ArticleId IdType="pubmed">26468545</ArticleId></ArticleIdList></Reference><Reference><Citation>Korber B. HIV signature and sequence variation analysis. In: Rodrigo A.G., Learn G.H., editors. Computational Analysis of HIV Molecular Sequences. Kluwer Academic Publishers; Dordrecht, The Netherlands: 2000. pp. 55&#x2013;72.</Citation></Reference><Reference><Citation>Shaw J., Jorba J., Zhao K., Iber J., Chen Q., Adu F., Adeniji A., Bukbuk D., Baba M., Henderson E., et al. Dynamics of evolution of poliovirus neutralizing antigenic sites and other capsid functional domains during a large and prolonged outbreak. J. Virol. 2018:92. doi: 10.1128/JVI.01949-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01949-17</ArticleId><ArticleId IdType="pmc">PMC5899205</ArticleId><ArticleId IdType="pubmed">29444940</ArticleId></ArticleIdList></Reference><Reference><Citation>Muslin C., Joffret M.L., Pelletier I., Blondel B., Delpeyroux F. Evolution and emergence of enteroviruses through intra- and inter-species recombination: Plasticity and phenotypic impact of modular genetic exchanges in the 5&#x2032; untranslated region. PLoS Pathog. 2015;11:e1005266. doi: 10.1371/journal.ppat.1005266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005266</ArticleId><ArticleId IdType="pmc">PMC4643034</ArticleId><ArticleId IdType="pubmed">26562151</ArticleId></ArticleIdList></Reference><Reference><Citation>Jegouic S., Joffret M.L., Blanchard C., Riquet F.B., Perret C., Pelletier I., Colbere-Garapin F., Rakoto-Andrianarivelo M., Delpeyroux F. Recombination between polioviruses and co-circulating coxsackie A viruses: Role in the emergence of pathogenic vaccine-derived polioviruses. PLoS Pathog. 2009;5:e1000412. doi: 10.1371/journal.ppat.1000412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000412</ArticleId><ArticleId IdType="pmc">PMC2669712</ArticleId><ArticleId IdType="pubmed">19412342</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakoto-Andrianarivelo M., Guillot S., Iber J., Balanant J., Blondel B., Riquet F., Martin J., Kew O., Randriamanalina B., Razafinimpiasa L., et al. Co-circulation and evolution of polioviruses and species C enteroviruses in a district of Madagascar. PLoS Pathog. 2007;3:e1911. doi: 10.1371/journal.ppat.0030191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.0030191</ArticleId><ArticleId IdType="pmc">PMC2134956</ArticleId><ArticleId IdType="pubmed">18085822</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Zhu S.L., Yoshida H., Yoneyama T., Miyamura T., Shimizu H. A Sabin 3-derived poliovirus recombinant contained a sequence homologous with indigenous human enterovirus species C in the viral polymerase coding region. J. Virol. 2005;79:12650&#x2013;12657. doi: 10.1128/JVI.79.20.12650-12657.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.20.12650-12657.2005</ArticleId><ArticleId IdType="pmc">PMC1235834</ArticleId><ArticleId IdType="pubmed">16188967</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu H., Thorley B., Paladin F.J., Brussen K.A., Stambos V., Yuen L., Utama A., Tano Y., Arita M., Yoshida H., et al. Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001. J. Virol. 2004;78:13512&#x2013;13521. doi: 10.1128/JVI.78.24.13512-13521.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.24.13512-13521.2004</ArticleId><ArticleId IdType="pmc">PMC533948</ArticleId><ArticleId IdType="pubmed">15564462</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew O., Morris-Glasgow V., Landaverde M., Burns C., Shaw J., Garib Z., Andre J., Blackman E., Freeman C.J., Jorba J., et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science. 2002;296:356&#x2013;359. doi: 10.1126/science.1068284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1068284</ArticleId><ArticleId IdType="pubmed">11896235</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuervo N.S., Guillot S., Romanenkova N., Combiescu M., Aubert-Combiescu A., Seghier M., Caro V., Crainic R., Delpeyroux F. Genomic features of intertypic recombinant Sabin poliovirus strains excreted by primary vaccinees. J. Virol. 2001;75:5740&#x2013;5751. doi: 10.1128/JVI.75.13.5740-5751.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.13.5740-5751.2001</ArticleId><ArticleId IdType="pmc">PMC114290</ArticleId><ArticleId IdType="pubmed">11390576</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavrilin G.V., Cherkasova E.A., Lipskaya G.Y., Kew O.M., Agol V.I. Evolution of circulating wild poliovirus and of vaccine-derived poliovirus in an immunodeficient patient: A unifying model. J. Virol. 2000;74:7381&#x2013;7390. doi: 10.1128/JVI.74.16.7381-7390.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.74.16.7381-7390.2000</ArticleId><ArticleId IdType="pmc">PMC112258</ArticleId><ArticleId IdType="pubmed">10906191</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C.F., Chen H.Y., Jorba J., Sun H.C., Yang S.J., Lee H.C., Huang Y.C., Lin T.Y., Chen P.J., Shimizu H., et al. Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient. J. Virol. 2005;79:12623&#x2013;12634. doi: 10.1128/JVI.79.20.12623-12634.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.20.12623-12634.2005</ArticleId><ArticleId IdType="pmc">PMC1235840</ArticleId><ArticleId IdType="pubmed">16188964</ArticleId></ArticleIdList></Reference><Reference><Citation>Acevedo A., Brodsky L., Andino R. Mutational and fitness landscapes of an RNA virus revealed through population sequencing. Nature. 2014;505:686&#x2013;690. doi: 10.1038/nature12861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12861</ArticleId><ArticleId IdType="pmc">PMC4111796</ArticleId><ArticleId IdType="pubmed">24284629</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignuzzi M., Wendt E., Andino R. Engineering attenuated virus vaccines by controlling replication fidelity. Nat. Med. 2008;14:154&#x2013;161. doi: 10.1038/nm1726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1726</ArticleId><ArticleId IdType="pubmed">18246077</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignuzzi M., Stone J.K., Arnold J.J., Cameron C.E., Andino R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature. 2006;439:344&#x2013;348. doi: 10.1038/nature04388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04388</ArticleId><ArticleId IdType="pmc">PMC1569948</ArticleId><ArticleId IdType="pubmed">16327776</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska D.A., Pallansch M.A., Cochi S.L., Kovacs S.D., Wassilak S.G.F., Thompson K.M. Updated characterization of post-OPV cessation risks: Lessons from 2019 Serotype 2 outbreaks and implications for the probability of OPV restart. Risk Anal. 2021;41:320&#x2013;328. doi: 10.1111/risa.13555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13555</ArticleId><ArticleId IdType="pmc">PMC7814395</ArticleId><ArticleId IdType="pubmed">32632925</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens R.J., Thompson K.M. Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: An essential oral poliovirus vaccine cessation risk management strategy. Epidemiol. Infect. 2017;145:217&#x2013;226. doi: 10.1017/S0950268816002302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268816002302</ArticleId><ArticleId IdType="pmc">PMC5197684</ArticleId><ArticleId IdType="pubmed">27760579</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurung S., Harris J.B., Eltayeb A.O., Hampton L.M., Diorditsa S., Avagyan T., Schluter W.W. Experience with inactivated polio vaccine introduction and the &#x201c;switch&#x201d; from trivalent to bivalent oral polio vaccine in the World Health Organization&#x2019;s western Pacific region. J. Infect. Dis. 2017;216(Suppl. S1):S101&#x2013;S108. doi: 10.1093/infdis/jiw574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw574</ArticleId><ArticleId IdType="pmc">PMC5853504</ArticleId><ArticleId IdType="pubmed">28838170</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams A., Boualam L., Diorditsa S., Gregory C., Jee Y., Mendoza-Aldana J., Roesel S. Maintaining polio-free certification in the World Health Organization western Pacific Region for over a decade. J. Infect. Dis. 2014;210(Suppl. S1):S259&#x2013;S267. doi: 10.1093/infdis/jiu164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu164</ArticleId><ArticleId IdType="pmc">PMC10424813</ArticleId><ArticleId IdType="pubmed">25316844</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo H.M., Zhang Y., Wang X.Q., Yu W.Z., Wen N., Yan D.M., Wang H.Q., Wushouer F., Wang H.B., Xu A.Q., et al. Identification and control of a poliomyelitis outbreak in Xinjiang, China. N. Engl. J. Med. 2013;369:1981&#x2013;1990. doi: 10.1056/NEJMoa1303368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303368</ArticleId><ArticleId IdType="pubmed">24256377</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauri M., Wilkinson A.L., Ropa B., Feldon K., Snider C.J., Anand A., Tallis G., Boualam L., Grabovac V., Avagyan T., et al. Notes from the field: Circulating vaccine-derived poliovirus Type 1 and outbreak response&#x2014;Papua New Guinea, 2018. MMWR Morb. Mortal. Wkly. Rep. 2019;68:119&#x2013;120. doi: 10.15585/mmwr.mm6805a6.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6805a6</ArticleId><ArticleId IdType="pmc">PMC6366675</ArticleId><ArticleId IdType="pubmed">30730867</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Yan D., Zhu S., Nishimura Y., Ye X., Wang D., Jorba J., Zhu H., An H., Shimizu H., et al. An insight into recombination with Enterovirus species C and Nucleotide G-480 reversion from the viewpoint of neurovirulence of vaccine-derived polioviruses. Sci. Rep. 2015;5:17291. doi: 10.1038/srep17291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep17291</ArticleId><ArticleId IdType="pmc">PMC4658552</ArticleId><ArticleId IdType="pubmed">26603565</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>